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Abstract
Fetal growth restriction (FGR) diagnosed before 32 weeks is identified by fetal smallness associated with Doppler
abnormalities and is associated with significant perinatal morbidity and mortality and maternal complications. Recent
studies have provided new insights into pathophysiology, management options and postnatal outcomes of FGR. In
this paper we review the available evidence regarding diagnosis, management and prognosis of fetuses diagnosed
with FGR before 32 weeks of gestation.
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Background
Fetal growth restriction (FGR) is both a common obstetric
condition and a major cause of perinatal morbidity and
mortality [1, 2]. Early FGR by definition is diagnosed at or
below 32 weeks and differs from late onset FGR also in
terms of its clinical manifestations, association with hyper-
tension [3], patterns of deterioration and severity of placen-
tal dysfunction [4, 5].
The perinatal outcome of FGR is dependent on the se-
verity of growth restriction; an estimated fetal weight
below the 3rd centile and/or abnormal umbilical artery
Doppler are strongly associated with adverse perinatal
outcome [6]. A recent study has shown how the inci-
dence of perinatal death is highest in those with a birth
weight below the 2.3rd centile, falling gradually with an
increasing birth weight up to the 80th and 90th centiles,
at which the lowest death rates occur [7].
FGR is a complex and multifactorial disorder affecting
the fetal development that often results in multiple peri-
natal complications [8–10] and currently represents a
major risk factors for long term poor neurological out-
come. FGR is also associated with poor postnatal growth
and numerous studies in both humans and animals have
shown an association between low birth weight and devel-
opment of cardiovascular disease including increased risk
of hypertension, diabetes, dyslipidemia and coagulation in
children and adults [9–16]. These observations were first
made in 1989 by Barker and colleagues and confirmed in
the last few decades [17, 18]. It has been postulated that
cardiovascular remodelling is due to hemodynamic
redistribution and adaptation to hypoxia and insufficient
nutrition [17–22].
At present there is no effective treatment to reverse the
course of FGR except delivery. Fetal growth restriction is
probably among the obstetric entities where there is the
greatest variation in clinical practice, in terms of monitor-
ing and recommended gestational age at delivery. Prenatal
recognition of FGR remains the main challenge in daily
obstetric practice. Correct surveillance, antenatal manage-
ment and timing of delivery can improve fetal and
neonatal outcomes.
Etiology
The causes of FGR are heterogeneous and can be classi-
fied as fetal, maternal, environmental, and placental. Small
fetuses can be divided into two groups: non-placenta
mediated growth restriction and placenta mediated [23].
The first group includes structural and chromosomal/gen-
etic anomalies (trisomies 13 and 18; genetic conditions such
as Russel Silver Syndrome), congenital infections (rubella,
cytomegalovirus, toxoplasmosis) [24] and inborn errors of
metabolism. The second and much more common group
includes medical conditions that can affect placental func-
tion: pre-eclampsia, chronic hypertension and gestational
hypertension are complicated by FGR in 30 to 40% of cases
[23]; diabetes is complicated by FGR in 10 to 20% of cases
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irrespective of glycemic control [25]; maternal vascular dis-
ease, renal disease, thrombophilia, autoimmune disease, can
lead to uteroplacental hypoperfusion thereby impairing fetal
growth [26]; hypoxemia secondary to cardiac, respiratory
and hematological disorders may also cause FGR.
Others maternal risk factors associated with an in-
creased risk of a SGA neonate are maternal age ≥35 years
and particulalry in women ≥40 years old [27], African
American [28] or Indian/Asian ethnicity [29], nulliparity
[30], social deprivation [31], body mass index (BMI) <20,
BMI > 25 [32], alcohol intake [33], drug use (with cocaine
use during pregnancy being the most significant) [34] and
cigarette smoking [35]. Singleton pregnancies following
IVF are also at increased risk for SGA [36]. Twin pregnan-
cies have a high incidence of FGR: about 20–30% of
dichorionic and 40% of monochorionic twin pregnancies
will suffer from FGR [37].
Definition and diagnosis
Multiple definitions of FGR have been suggested over the
decades by National and Internationl Societies and experts
(Table 1) [38, 39]. Despite this, there is currently no
agreed upon diagnostic criteria for FGR. The American
College of Obstetricians and Gynecologists (ACOG)
defines FGR as an estimated fetal weight less than the 10th
centile [40]. The Royal College of Obstetricians and
Gynaecologists (RCOG) uses fetal abdominal circumfer-
ence (AC) or estimated fetal weight (EFW) <10th centile
to diagnose a FGR fetus [41]. Other Authors have sug-
gested a cut off of the 3rd centile to detect pregnancies at
higher risk of adverse outcomes [42]. In 2002 the
TRUFFLE group, which included 20 European Perinatal
experts, defined fetal growth restriction as the combin-
ation of abdominal circumference <10th centile and umbil-
ical artery Doppler pulsatility index (PI) >95th percentile
[3]. Similarly, after prospectively assessing the adverse
perinatal outcomes in over 1100 pregnancies where EFW
at inclusion was <10th centile, the PORTO group defined
FGR as a combination of fetal smallness (EFW <5th cen-
tile) and umbilical artery Doppler PI >95th percentile [6].
More recently, early FGR has been defined by a consensus
committe of international fetal medicine experts with soli-
tary parameters ither EFW <3rd centile, AC <3rd centile or
absent umbilical artery end diastolic flow [43].
In its latest practice bulletin the ACOG acknowledges
the fact that terminology for classifying fetuses and new-
borns who have failed to achieve normal weight is incon-
sistent [40]. Indeed, the acronyms SGA and FGR are often
used interchangeably. However, fetuses with a weight <10
th percentile may be constitutionally small but healthy and
not necessarily growth restricted. On the other hand, an
estimated weight >10th percentile does not necessarily
denote normal fetal growth. Because of this, FGR
shouldbe referred to fetuses with pathological smallness
caused by an underlying functional problem and hence a
definition including not only a biometric cut off but also
Doppler indices of feto-placental function is currently
agreed in most Fetal Medicine Units [3, 6, 43, 44].
FGR may also be classified by gestational age at onset as
early and late, with an arbitrary cut-off conventionally set at
32 weeks: the extremes of the clinical spectrum of FGR dif-
fer not only for gestation at onset, but also for clinical mani-
festations, patterns of fetal deterioration, association with
hypertensive disorders of the pregnancy and severity of pla-
cental dysfunction [45, 46]. Fetuses with late-onset disease
do not present the same sequence of Doppler deterioration
described for early-onset FGR [6]. Early-onset FGR repre-
sents 20–30% of all FGR and is associated with gestational
hypertension and/or pre-eclampsia in up to 70%. On the
other hand, late-onset FGR, which represents approximately
70–80% of cases of FGR, shows a weaker association with
hypertensive disorders of the pregnancy, roughly 10% [6].
A prerequisite for a correct diagnosis of FGR is accurate
dating of the pregnancy, most usually in the first trimester.
The Hadlock formula is the most widely accepted method
of estimating fetal weight using a composite sonographic
measurement of fetal head, abdomen, and femur [47]. Fetal
size is influenced by race, ethnicity, sex, parity, maternal
Table 1 FGR definition in recent literature
Institution / Author FGR definition
Baschat et al 2007 [101] Combination of small fetal AC with elevated
UA Doppler blood flow resistance
Cochrane 2013 [65] Failure to reach the growth potential
DIGITAT 2012 [38] EFW or AC <10th centile for gestational age
ACOG 2013 [40] Fetuses with EFW <10th centile for
gestational age
RCOG 2013 [41] Small–for–gestational age (SGA) refers to an
infant born with a birth weight less than the
10th centile.
Fetal growth restriction (FGR) is not synonymous
with SGA.
SOGC 2013 [39] Intrauterine growth restriction refers to a fetus
with a EFW <10th centile on ultrasound that,
because of a pathologic process, has not
attained its biologically determined growth
potential.
PORTO 2013 [6] EFW < 5th percentile & umbilical artery PI
>95th percentile
TRUFFLE 2013 [3] AC < 10th percentile & umbilical artery PI
>95th percentile
Gordijin et al 2016 [43] AC <3rd centile OR EFW <3rd centile OR AREDF
OR
Both of the following: 1) EFW or AC < 10th
centile and 2) UtA PI >95th centile OR UA PI
>95th centile.
AC abdominal circumference
AREDF absent/reversed umbilical artery end diastolic flow
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size and genetic factors [48, 49]. In the 1990s, Gardosi et al.
developed a method that used customized birth weights to
identify the growth potential for individual fetuses: ante-
natal growth charts were customized for maternal charac-
teristics including height, weight, ethnic origin and parity
[50, 51]. The use of customized growth charts is purported
to increase the antenatal detection of fetal growth restric-
tion, improving the distinction between normal and abnor-
mal growth, but whether this improves clinical outcomes
still has to be demonstrated [51]. Customization is ques-
tioned by Intergrowth-21st according to which growth pat-
terns in healthy pregnancies are not considered to be
modulated by ethnic and environmental conditions [52].
Ultrasound assessment of fetal anatomy and amniotic
fluid volume is complementary to the Doppler investiga-
tion of fetoplacental circulation to distinguish FGR from
constitutionally small fetuses and to identify the most
likely underlying etiology of the fetal smallness (e.g., an-
euploidy, viral infection, genetic syndromes). The role of
determining the karyotype is very controversial; it may
be offered in cases where there is a dissociation between
growth, amniotic fluid and Doppler.
Screening
Early screening to predict the likelihood of a FGR fetus in-
clude medical and obstetric history, uterine artery Doppler
and maternal serum parameters [53]. Uteroplacental Dop-
pler is the most powerful predictor of the clinical deterior-
ation and the circumstances surrounding delivery [54]. The
systematic review and meta-analysis conducted by Cnossen
et al. in 2008 established uterine artery Doppler ultrasonog-
raphy as a predictor of FGR, providing a more accurate
prediction when performed in the second trimester than in
the first-trimester [55]. Numerous studies have also shown
that some maternal biochemical markers (e.g. pregnancy
associasted plasma protein-a, PAPP-A; alfa-fetoprotein,
AFP; human chorionic gonadotropin, hCG; Inhibin A) are
associated with placental function and fetal growth, and
their levels are altered in SGA and FGR pregnancies [56]. A
low level first trimester PAPP-A should be considered a
major risk factor for delivering a SGA neonate; the combin-
ation of uterine artery Doppler and maternal serum
markers appears promising for improving prediction of
SGA fetus, although predictive values are still poor [57–59].
Use of combination testing in the second trimester appears
to predict adverse outcome related to placental insuffi-
ciency more effectively than first trimester screening [60].
Role of fetal Doppler in FGR
The fetal vessels that are more commonly examined in-
clude umbilical artery, middle cerebral artery, and
ductus venosus [61].
Early-and late-onset FGR epitomize two distinct clinical
phenotypes of placental dysfunction and differ significantly
in clinical progression. Early-onset FGR is associated with
high impedance utero placental perfusion which in turn
leads to elevated umbilical artery blood flow resistance once
villous damage exceeds 30% [45].
The relationship between fetal size and growth and
fetal Doppler indices in FGR is complex but in general
Doppler deterioration is associated with absolute fetal
size rather than growth velocity [62].
Late-onset FGR is more common but less severe with
absent or mild placental abnormalities; umbilical artery
Doppler may be normal, but fetuses may react with
decreased middle cerebral artery (MCA) impedance in
response to hypoxemia [63].
Umbilical artery Doppler
Umbilical artery Doppler is the only measure that pro-
vides both diagnostic and prognostic information for the
management of FGR [64]. A Cochrane systematic review
reported that the use of umbilical artery Doppler was as-
sociated with a reduction in perinatal deaths, inductions
of labor and cesarean deliveries [65]. Also according to
RCOG the use of umbilical artery Doppler in a high-risk
population has been shown to reduce perinatal morbid-
ity and mortality, and should be the primary surveillance
tool in the SGA fetus [41].
Umbilical artery flow identifies different degrees of im-
paired placental function. Absent or reversed end diastolic
flow (AEDF or REDF) indicates an important reduction of
blood flow and severe fetal deterioration.
Thanks to longitudinal studies of high-risk pregnancies,
we know that the the transition from AEDF to REDF may
be slow and gradual in early FGR. Absent end-diastolic
velocities in the umbilical artery, if not associated with se-
vere maternal disease, can last for days and weeks before
abnormal heart rate pattern or delivery [66].
Reverse end-diastolic flow velocity represents an ex-
treme abnormality in waveform and resistance, with a
perinatal mortality of 50% and significant perinatal mor-
bidity [67]. It has also been demonstrated that FGR fetuses
with absent or reverse end-diastolic flow in the umbilical
artery not only have an increased fetal and neonatal mor-
tality but also a higher incidence of long-term permanent
neurologic damage when compared with FGR fetuses with
positive diastolic flow in the umbilical circulation [68].
Middle cerebral artery Doppler
A condition of chronic hypoxia determines a fetal flow
redistribution that manifests as vasodilatation in the
brain circulation. Cerebral vasodilatation, easily detect-
able as a reduction in the PI of the middle cerebral
artery (MCA) represents an adaptative mechanism in
response to hypoxia.
Recently published data emphasize the association
between abnormal MCA PI and adverse perinatal and
Dall’Asta et al. Maternal Health, Neonatology, and Perinatology  (2017) 3:2 Page 3 of 12
neurological outcome [64]. MCA may be valuable for
the identification of adverse outcome among late-onset
FGR though its role in prediction is weak, independ-
ently of umbilical artery Doppler, which is often normal
in these fetuses [69–71]. The cerebroplacental ratio
(CPR) quantifies the redistribution of cardiac output by
dividing the Doppler indices of the middle cerebral ar-
tery (MCA) with that of the umbilical artery. The
PORTO study demonstrated the association between
redistribution, either isolated or associated with umbil-
ical artery PI >95th centile, and adverse perinatal out-
come [6, 63]. More recent data have shown
significantly lower MCA PI and CPR among fetuses
with EFW <10th centile diagnosed gestation beyond
32 weeks who experienced adverse perinatal outcomes
in terms of intrapartum distress and abnormal cord pH
[72]. Of note, such abnormal Doppler patterns have
been related to histological signs of placental insuffi-
ciency [73]. It is estimated that in late-onset FGR fe-
tuses abnormal CPR is present before delivery in 20 to
25% of cases [74]. Of note, it is important to underline
that MCA Doppler is currently not included in any
protocol for the diagnosis and the management of early
FGR fetuses as insufficient data exists in prospective
studies to define its role.
Ductus venosus Doppler
Doppler examination of the ductus venosus (DV) plays
an important role in the management of fetuses with
early fetal FGR with the hope of improving the timing of
delivery and outcome.
FGR is associated with increased ductus venosus (DV)
shunting, and increasing impedance in the umbilical ar-
tery, has a graduated effect on the degree of shunting
[20]. In contrast to alterations in umbilical artery and
middle cerebral artery, which are early signs of adverse
outcome, longitudinal studies have demonstrated that
DV flow waveforms become abnormal only in advanced
stages of fetal compromise [75–78].
It has been showed that the PI of the DV is related to
pH at birth, with higher DV pulsatility associated with
lower pH at birth [79].
In 2001 Hecher et al. described the time sequence of
changes in fetal monitoring variables in fetal growth re-
striction; they found that ductus venosus PI and short-
term variation of fetal heart rate are important indicators
for the optimal timing of delivery before 32 weeks of
gestation and correlate with fetal outcome at delivery [78].
Ferrazzi et al identified the temporal sequence of abnor-
mal Doppler changes in the fetal circulation in early
growth restricted fetuses. Early changes occurred in
umbilical and middle cerebral arteries (AEDF and brain
sparing respectively); late changes were significantly asso-
ciated with perinatal death and included umbilical artery
REDF and abnormalities in the DV Doppler (reverse A-
wave in particular) [2]. Another study demonstrated that
absent or reverse velocities in the DV during atrial
contraction are associated with perinatal mortality inde-
pendently of the gestational age at delivery [79]. Bilardo et
al. showed that during the last 24 h before delivery DV
pulsatility index for veins (PIV) and umbilical artery PI
were significantly higher and STV lower in the adverse
outcome group, while 2–7 days before delivery only DV
PI was significantly higher. These results indicate that DV
PI measurement is a good predictor of perinatal outcome
and may be useful in determining the timing of the deliv-
ery in of early FGR fetuses [80]. In about 50% of cases,
abnormal DV precedes the loss of short-term variability in
computerized cardiotocography (CTG) [79], and in about
90% of cases it is abnormal 48 to 72 h before the biophys-
ical profile (BPP) [80].
Cardiac and aortic isthmus Doppler
Cardiac Doppler allows the evaluation of the functional-
ity of the heart with the deterioration of FGR. Systolic
and diastolic heart function, atrio-ventricular flows and
ventricular outflows can be studied.
In 1988 a prospective longitudinal study by Rizzo et al.
described the physiological patterns of blood flow velocity
waveforms in normal and in SGA fetuses. In normal fetuses
the ratio between the E velocity (early passive ventricular
filling) and the A velocity (active ventricular filling during
atrial contraction) increased progressively during pregnancy
in both transmitral and transtricuspidal waveforms. In SGA
fetuses, the E/A ratios did not increase during pregnancy
and the values obtained were significantly lower than in
normal fetuses [81]. In FGR fetuses the time to peak vel-
ocity at the level of the ascending aorta and pulmonary is
also lower than in normal fetus, indicating an impairment
of myocardial contractility [82].
The literature suggests a potential role for Doppler im-
aging of the aortic isthmus (AoI) in the clinical surveil-
lance of fetuses with severe FGR. Retrograde flow in the
AoI in growth-restricted fetuses correlates strongly with
adverse perinatal outcome and neurological deficit in the
infant [83, 84].
The myocardial performance index (MPI) is a more
recently described parameter that may be useful in fetal
monitoring. MPI, AoI PI, together with DV PIV, in-
crease with progressive fetal deterioration. According
to Cruz-Martinez et al., at the last examination before
delivery the proportion of increased MPI (70.4%) was
significantly higher than that of abnormal AoI PI
(55.7%) and DV PIV (47.8%) [85]. A significantly higher
MPI in growth restricted fetuses compared to appropri-
ately grown fetuses was also demonstrated by Hassan et
al, who additionally found a potential role of the MPI
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in the prediction of arterial and venous Doppler abnor-
malities in small for gestational age fetuses [86].
Management
Despite being one of the most relevant and most com-
monly studied conditions in modern obstetrics, there
has not been consensus among International Guidelines
regarding the optimal management of early onset FGR
in terms of monitoring and recommended gestational
age at delivery, which can be due to the lack of compar-
ability among studies and the paucity of randomized
controlled trials available [3, 65, 87, 88]. Nevertheless,
more recent data suggest that reliable protocols of sur-
veillance and management are emerging now [3, 88].
When managing FGR fetuses clinicians focus on EFW,
gestational age and fetal Doppler. A threshold of about
500 grams is often considered the value of EFW above
which a fetus is potentially surviving outside the uterus,
and which must be considered especially when evaluating
the options of termination of pregnancy, invasive testing
and delivery of a potentially viable fetus. Furthermore, an
EFW <3rd centile has been described as predictive of poor
outcome [89].
Importantly, gestational age is the most significant deter-
minant of both survival and intact survival [46]. A remark-
able reduction in the gestational age cut off for neonatal
survival has been achieved, and current neonatal practice
has lead to the survival of fetuses born from 22 weeks on-
wards [90]. Recently published data report a better than ex-
pected prognosis for periviable small fetuses [91], however
according to Visser et al. [92] active intervention by delivery
of early FGR fetuses should not be recommended before
26 weeks as their outcome is comparable to that of AGA
infants born at a 2-weeks earlier gestational age. Counseling
plays a crucial role, however in a scenario of lacking
evidence it is usually individualized on the basis of the clin-
ical features and the option of pregnancy termination may
be discussed when legally available.
Monitoring fetuses by using umbilical artery Doppler
has been demonstrated to reduce the perinatal death rate
[66, 69] though there are few clues as to when delivery
should be undertaken. Abnormal umbilical artery PI is a
feature of FGR according to the TRUFFLE group as a PI
above the 95th centile together with AC <10th centile are
the diagnostic criteria for FGR; a raised umbilical PI is
suggestive of severe placental disease, which represents
the most common cause for FGR [69]. However, as re-
ported by Figueras et al. [64] the management based on
umbilical artery alone cannot be effective in those cases of
mild placental disease, which account for a proportion of
the early onset FGR fetuses, which show reduced MCA
pulsatility or cerebroplacental ratio (CPR) (or cerebro-
umbilical C-U ratio). Unfortunately, there is not enough
evidence to consider MCA Doppler effective in managing
FGR fetuses. A recent review by DeVore et al [93] reports
that an abnormal CPR is associated with adverse pre- and
post-natal outcomes even in fetuses with early-onset SGA;
however, it has never been demonstrated whether deliver-
ing earlier fetuses who show features of redistribution
could add any benefit [64, 93, 94].
Ductus venosus (DV) Doppler is currently used in most
European Specialist Perinatal Units as the reference for
the management of FGR fetuses before 32 weeks. DV has
been demonstrated to be the single strongest Doppler par-
ameter to predict the short term risk of fetal death in early
onset FGR [64] and there is good correlation between ab-
normal DV waveform and late stage acidemia. Absent or
reversed A-wave have been reported to be associated with
increased risk of intrauterine fetal death (40–70%) inde-
pendently of the gestational age at delivery; DV PI >95th
centile also confers higher risk of adverse outcome, al-
though at lesser extent than that of reversed or absent A-
wave [87]. According to Hecher et al. [76] DV is, together
with computerized cardiotocography (cCTG), the param-
eter which last modifies before delivery, and the TRUFFLE
group has demonstrated the benefits of a longer stay in
utero, especially with regard to long term outcomes.
The biophysical profile has not been demonstrated to be
beneficial in high risk pregnancies in terms of perinatal
deaths and Apgar <7 at 5 min [33], it is not an accurate
predictor of fetal acidemia [24, 34], and there is concern
regarding the high false positive and false negative rate
(up to 23% of instances of intrauterine fetal death in
fetuses with BPP >6 and 11% in those with BPP >8) re-
ported in early-onset very preterm FGR fetuses [46].
Conventional cardiotocography (CTG), along with the
assessment of the baseline, the long term variability, accel-
erations and decelerations of the fetal heart rate, currently
represents one of the main tools for the antenatal surveil-
lance of the fetal wellbeing. CTG has been compared to
no intervention in a Cochrane review of four randomized
control trials. No improvement in perinatal mortality was
shown [65, 95] and currently there is no other evidence
supporting the use of conventional CTG in FGR fetuses
[65, 89]. Short-term variability (STV) can be detected only
using cCTG and becomes abnormal in the case of ad-
vanced fetal deterioration [77]. Current evidence suggests
that cCTG is sensitive in the detection of advanced fetal
deterioration providing information similar to DV reverse
A-wave for the short-term prediction of fetal death.
Uterine artery Doppler may predict poor outcome in
FGR but does not provide information sufficiently sophisti-
cated to be considered effective in the management of the
FGR fetuses [89, 96–98].
Which parameter is used to monitor FGR fetuses is
not a more important issue than how often these fetuses
should be assessed. A stage-based management protocol
suggested by Figueras et al. [94], recommends fetal
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monitoring twice weekly up to 34 weeks if umbilical
artery AEDF, every 24 to 48 h up to 30 weeks if reverse
diastolic flow in the umbilical artery (REDV) or DV-PI >
95th centile, and every 12 to 24 h up to 26 weeks if
spontaneous FHR decelerations, reduced STV (<3 ms)
in the computerised cardiotocography, or reverse atrial
flow in the DV.
There is no data as regards the decision for inpatient
versus outpatient management of FGR fetuses. Most
cases of isolated FGR are monitored in an outpatient
setting even though the decision for inpatient monitor-
ing can be taken on a subjective basis. Of note, 60–70%
of cases of early FGR are associated with hypertensive
complications of the pregnancy [3]. In such cases we
believe that admission is advisable despite the lack of
clinical data supporting this view.
Timing of delivery
At present there is no effective intervention for FGR
except delivery, and especially for early-onset FGR the
timing is crucial and requires a balance between the
risks of prematurity and the possibility of stillbirth
and organ damage due to inadequate tissue perfusion
[64, 90], unless severe maternal complications super-
vene [3, 88, 99].
Currently there is no consensus on what is the most
appropriate trigger for delivery as the evaluation of the
fetal status by Doppler indices and CTG cannot be
assessed independently from the gestational age, which
is the most significant determinant of both survival and
intact survival, and fetal weight [90].
Though the GRIT study showed no clear benefit in de-
livering immediately or delaying delivery when a fetus is
thought to be compromised, evidence from the TRUFFLE
study shows how important it is to delay delivery in order
to reduce the risk of cerebral palsy and poor neurodeve-
lopmental outcome [79, 99] in this case based on deterior-
ation in both the ductus venosus and STV from
computerized CTG. However, this can be safely achieved
only through protocols that integrate the best available
evidence and reducing clinical practice variation [64].
Baschat et al. suggested the absent or reversed umbilical
artery end diastolic velocity (AREDV) as the trigger for
delivery, as it seems to have an independent impact on
neurodevelopment from the late second trimester onward
as representative of deepening hypoxemia [54], though
this strategy was not tested in a prospective study.
The GRIT study was the first RCT which aimed to as-
sess the timing for delivering FGR fetuses and concluded
that “uncertainty” of the clinician as to whether deliver or
not to deliver is related to the timing of delivery, which
varied on average by only 4 days. Furthermore, fetuses
with severe DV abnormalities at or beyond 28 weeks
should be delivered after completion of steroids as there is
evidence that reversed A-wave in the DV increases the
risk of intrauterine fetal death at any gestational age [99].
According to the stage-based management protocol
suggested by Figueras et al. [94] delivery by Caesarean
section should be recommended at or after 34 weeks in
case of umbilical artery AEDV, at or after 30 weeks if
umbilical artery REDF or DV-PI > 95th centile and at or
after 26 weeks if spontaneous fetal heart rate (FHR) de-
celerations, reduced short-term variability (<3 ms) in the
cCTG, or reverse atrial flow in the DV Doppler.
The TRUFFLE is the only randomized controlled study
which has evaluated a standardized monitoring and de-
livery protocol focussed on computerized CTG and DV
Doppler. The “late” DV group (absent or reversed A-
wave) was associated with significant improval in the
rate of survival without impairment when compared to
computerized CTG, and delivery was recommended in
case of umbilical artery REDF between 30 and 32 weeks,
umbilical artery AEDF between 32 and 34 weeks, or um-
bilical artery PI >95th centile beyond 34 weeks. Safety
nets for the computerised CTG were used in the
TRUFFLE protocol, and may have contributed to the
excellent outcomes in term of mortality and survival
without impairment [3, 87].
Despite accumulating evidence suggesting that cere-
bral redistribution, defined by a reduction in the MCA
PI below the 5th centile or a reduction in the C-U ratio
below the 2.5th centile, may not be an entirely protect-
ive phenomenon, currently there is no evidence to rec-
ommend delivery before 34 weeks in fetuses who show
features of cerebral redistribution [45, 64, 94].
Regarding the mode of delivery, 97% of women in
TRUFFLE had Caesarean deliveries, compared with 98
and 85% in the cohorts reported by Baschat and GRIT,
respectively [3, 87, 88, 100, 101]. It is of note that no
studies have evaluated the optimal mode of delivery in
early FGR fetuses.
Outcomes
Early growth restricted fetuses by definition carry at
least one of the major risk factors for perinatal morbid-
ity and mortality, i.e. low birthweight and prematurity.
Early and late-onset FGR are both associated with poor
short- and long-term neurodevelopmental outcome,
and also with cardiovascular and metabolic complica-
tions particularly in case of birth weigth <3rd centile
and gestation at delivery <26 weeks [64, 93]. Additionally,
the cause of the growth restriction can impact on the
short and long term prognosis, so especially for se-
verely early growth restricted fetuses it is important
to identify the cause by offering karyotyping and viral
screen [32, 90]. This can allow to distinguish between
fetuses who are affected by true FGR, and those who
are constitutionally small (SGA) but with a guarded
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prognosis, particularly if the birthweight is below the
3rd centile [102].
Few data exist regarding periviable growth restricted
babies, a category which is commonly associated with
poor outcome [92]. In 2014 Story et al [102] reviewed
the outcomes of 20 FGR fetuses diagnosed <24 weeks
and EFW <3rd centile reporting a 67% preterm delivery
rate and a better than expected survival to neonatal dis-
charge rate of 60%. Such surprisingly good outcomes
were confirmed by recently published data from a wider
UK cohort of 245 cases of periviable FGR fetuses who
showed an overall 41% neonatal survival rate and a 15%
rate of delivery beyond 36 weeks, concluding that at a
periviable gestational age both SGA and FGR can
present in similar ways, and differentiation at the earliest
possible time is crucial to allow appropriate management
and counseling [91].
After 26 weeks the best results in terms of short term
and 2-year outcomes were reported by the TRUFFLE
group [3, 87], with 8% overall mortality (3% beyond
30 weeks), 24% severe neonatal morbidity, and low rates
of bronchopulmonary dysplasia and poor neurodevelop-
mental outcome despite including fetuses who were on
average 1 week younger and 300 g lighter if compared to
the other RCT (GRIT) conducted on FGR fetuses [88].
Overall 69% of the 503 included fetuses survived without
severe neonatal morbidity and these results were ex-
plained as a consequence of a more detailed and stan-
dardized protocol of surveillance. Allocation to delivery
on the basis of absent/reversed A-wave in the DV
accounted for a non significant increase in the stillbirth
rate and a significant lower rate of abnormal neurodeve-
lopmental outcome compared to the computerized CTG
group, irrespective of the gestational age at inclusion
[87]. According to Baschat et al. in-early onset FGR the
nutritional and vascular restriction in placental function
is limited with umbilical artery AREDV, and particularly
reversed end-diastolic velocity is an independent risk
factor for adverse motor and cognitive development
[54]. Later in life no differences were reported in the
rates of severe disability and individual domain scores
between the two delivery arms in the GRIT study [86,
98] and results were comparable to other preterm co-
horts without FGR [54]. Recently published data con-
cerning short term survival of severe growth restricted
fetuses across gestation at diagnosis and delivery are re-
ported in Tables 2, 3 and in Figs. 1 and 2.
Future directions
Delivery is acknowledged to be the only treatment for
FGR at present and the most important studies have
Table 2 Short term survival across gestation at diagnosisa
Gestation at diagnosis Survival N Perinatal death (IUD + NND) N Survival % Perinatal death (IUD + NND) %
22–23 weeks 49 69 41% 59%
24–25 weeks 52 42 55% 45%
26–27 weeks 126 22 85% 15%
28–29 weeks 188 15 93% 7%
30–31 weeks 164 2 99% 1%
Source: Data has been collated and fused from TRUFFLE 2013 [3] and Lawin O’Brien et al [91]
IUD intrauterine death
NND neonatal death
aTerminations of pregnancy (TOP) excluded
Table 3 Short term survival across gestation at deliverya,b
Gestation at delivery Survival N Perinatal death (IUD + NND) N Survival % Perinatal death (IUD + NND) %
22–23 weeks 1 7 13% 87%
24–25 weeks 0 30 0% 100%
26–27 weeks 51 52 49% 51%
28–29 weeks 141 27 84% 16%
30–31 weeks 173 10 95% 5%
32–33 weeks 111 5 96% 4%
>34 weeks 87 4 96% 4%
Source: Data has been collated and fused from TRUFFLE 2013 [3] and Lawin O’Brien et al [91]
IUD intrauterine death
NND neonatal death
aLawin-O’Brien et al [91] 4 cases missing gestation at delivery
bTerminations of pregnancy (TOP) excluded
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focused on how to monitor and when to deliver FGR
fetuses in order to optimize the perinatal outcomes.
Currently there are no evidence-based therapies for early
onset FGR but over the last decades it has been suggested
that other approaches, namely nitric oxide (NO), Sildenafil
and maternal plasma volume expansion may play a role in
prolonging pregnancies and reducing Doppler deterioration
in FGR fetuses [103–106].
Early FGR is associated with hypertensive disorders of
the pregnancy and preeclampsia in up to 73 and 52% of the
cases respectively [3]. It is hypothesized that the syndrome
of pre-eclampsia stems from a failure of placental implant-
ation and development [107] which leads to a failure in
physiologic increase of uterine perfusion during pregnancy.
Nevertheless, uteroplacental insufficiency is also a widely
acknowledged cause of FGR. In 2001 Parra et al [103]
demonstrated that in pregnancies complicated by FGR
NO production is impaired if compared to normal and
hypertensive cases, whereas more recent data suggest
an increased NO production in FGR fetuses [108]. It is
uncertain how and why NO pathways are abnormal in
FGR fetuses and, most importantly, no data have sup-
ported a significant improvement in perinatal outcomes
in mothers treated with NO. On the other hand, some
evidences have shown that in pregnancies complicated
by hypertension and growth restriction the combined
therapy consisting in plasma volume expansion with
enriched physiological solution and NO donors can im-
prove maternal hemodinamics, prolong the pregnancy
and increase the birthweight [106].
Animal models of fetal growth restriction have demon-
strated that the phosphodiesterase 5 inhibitor Sildenafil
citrate increases birth weight and improves uteroplacental
blood flow and there is also little evidence from a study
done on humans that Sildenafil increases birthweight in
pregnancies complicated by ealy-onset preeclampsia [109].
STRIDER is the acronim of an ongoing prospective individ-
ual participant data study which will add clinical information
as to whether Sildenafil can be safely and effectively used in
human pregnancies [104].
Last, but not least, studies conduced on sheep have
shown that local treatment at the uteoplacental site with

































Fig. 2 Short term survival across gestation at delivery
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the pro-angiogenetic factor VEGF-A improves fetal
growth in growth restricted ewes [110, 111]. VEGF-A
treatment was associated with a significant and long term
(at least 4 weeks) increase in bloodflow and reduction in
contractility of the uterine arteries in both pregnant and
non pregnant animals [112]. These findings give hope that
VEGF-A gene therapy can reverse the impaired uteropla-
cental perfusion which is associated with most cases of
FGR even in humans, however further studies on both
animal and human models are needed before any clinical
application could be contemplated.
Conclusions
In summary, a conservative management focused on the
identification of etiology in periviable growth restricted
fetuses is recommended, as prognosis can vary widely
despite similar ultrasound findings at diagnosis. Beyond
26 weeks the current evidence suggests that a detailed
surveillance protocol integrating fetal ductus venosus
Doppler and computerized CTG allows better outcomes
and delivery only when one or both become abnormal.
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